- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Eris Lifesciences Q3 & 9M FY26 results show solid growth!
**Business Performance:** Consolidated Revenue jumped 11% YoY to ₹807 Cr in Q3, with 9M revenue up 8.4% to ₹2,373 Cr. Adjusted Profit After Tax (PAT) soared 38.5% in Q3 to ₹120 Cr (9M up 39.3% to ₹380 Cr), fueled by lower interest and tax costs. Domestic Branded Formulations (DBF) grew 10%, while International Business rocketed 45% in Q3!
**Growth & Strategy:** Eris is sharpening its focus by discontinuing low-profit tail-end DBF brands, aiming for better margins. A big push in Insulins: market share for RHI Cartridges has tripled, and they're targeting 25% in the overall RHI+Glargine market. Watch out for new Insulin Analogues & GLP-1 launches!
**Recent Developments:** Exciting launch of Esaxerenone, India's first next-gen hypertension management drug. Insulin manufacturing is scaling up at Bhopal, preparing for commercial launches of new variants by FY27.
**Key Financial Metrics:** Q3 EBITDA grew 13% to ₹282 Cr (margin 34.9%). 9M EBITDA up 11% to ₹847 Cr (margin 35.7%). Adj. EPS at ~₹9 for Q3, ~₹28 for 9M.
**Management Commentary / Outlook:** Management projects FY26 Consolidated Revenue around ₹3,200 Cr & EBITDA ~₹1,150 Cr. International business eyes ₹550-600 Cr revenue in FY27, backed by strong EU-CDMO orders. Debt reduction is a priority, aiming for Net Debt/EBITDA below 1.5x by December 2026. #ErisLifesciences #Pharma #Investing